Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Merola

Showing results (311-320 of 394) with videos related to

Pageof 40
Sort By:
Dermatology and Therapy|January 21, 2021
Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis RegistryAlice B Gottlieb, Joseph F Merola, Joshua Cirulli, et al.
ACR Open Rheumatology|February 28, 2024
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis RegistryPhilip J Mease, Alexis Ogdie, John Tesser, et al.
ACR Open Rheumatology|October 4, 2024
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled StudyPhilip J Mease, Xenofon Baraliakos, Vinod Chandran, et al.
Journal of the American Academy of Dermatology|October 18, 2023
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trialJoseph F Merola, Lawrence Charles Parish, Lyn Guenther, et al.
The Journal of Investigative Dermatology|February 9, 2025
Inter-Rater and Intra-Rater Reliability of the Cutaneous Lupus Activity-Investigator Global Assessment-Revised InstrumentJoseph F Merola, Arianna J Zhang, Beth A Childs, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 13, 2022
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension StudyLaura C Coates, Iain B McInnes, Joseph F Merola, et al.
Patient Preference and Adherence|July 2, 2020
Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country StudyDaniel Aletaha, M Elaine Husni, Joseph F Merola, et al.
Journal of the American Academy of Dermatology|December 20, 2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasisAndrew Blauvelt, Phoebe Rich, Howard Sofen, et al.
Journal of the American Academy of Dermatology|June 23, 2020
Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology HospitalistsOmid Zahedi Niaki, Milan J Anadkat, Steven T Chen, et al.
Lancet (London, England)|February 10, 2020
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trialChristopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, et al.
Pageof 40

Showing results (311-320 of 394) with videos related to

Sort By:
Pageof 40
Dermatology and Therapy|January 21, 2021
Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis RegistryAlice B Gottlieb, Joseph F Merola, Joshua Cirulli, et al.
ACR Open Rheumatology|February 28, 2024
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis RegistryPhilip J Mease, Alexis Ogdie, John Tesser, et al.
ACR Open Rheumatology|October 4, 2024
Persistent Patient-Level Effect of Guselkumab at Consecutive 8-Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2-Year, Phase 3, Randomized, Controlled StudyPhilip J Mease, Xenofon Baraliakos, Vinod Chandran, et al.
Journal of the American Academy of Dermatology|October 18, 2023
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trialJoseph F Merola, Lawrence Charles Parish, Lyn Guenther, et al.
The Journal of Investigative Dermatology|February 9, 2025
Inter-Rater and Intra-Rater Reliability of the Cutaneous Lupus Activity-Investigator Global Assessment-Revised InstrumentJoseph F Merola, Arianna J Zhang, Beth A Childs, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 13, 2022
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension StudyLaura C Coates, Iain B McInnes, Joseph F Merola, et al.
Patient Preference and Adherence|July 2, 2020
Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country StudyDaniel Aletaha, M Elaine Husni, Joseph F Merola, et al.
Journal of the American Academy of Dermatology|December 20, 2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasisAndrew Blauvelt, Phoebe Rich, Howard Sofen, et al.
Journal of the American Academy of Dermatology|June 23, 2020
Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology HospitalistsOmid Zahedi Niaki, Milan J Anadkat, Steven T Chen, et al.
Lancet (London, England)|February 10, 2020
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trialChristopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, et al.
Pageof 40